Efficacy  ||| S:0 E:9 ||| NNP
of  ||| S:9 E:12 ||| IN
595nm  ||| S:12 E:18 ||| CD
pulsed  ||| S:18 E:25 ||| CD
dye  ||| S:25 E:29 ||| JJ
laser  ||| S:29 E:35 ||| NN
therapy  ||| S:35 E:43 ||| NN
for  ||| S:43 E:47 ||| IN
Mibelli  ||| S:47 E:55 ||| NNP
angiokeratoma  ||| S:55 E:69 ||| VBD
To  ||| S:69 E:72 ||| TO
retrospectively  ||| S:72 E:88 ||| VB
study  ||| S:88 E:94 ||| VB
the  ||| S:94 E:98 ||| DT
clinical  ||| S:98 E:107 ||| JJ
efficacy  ||| S:107 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
595nm  ||| S:119 E:125 ||| CD
pulsed  ||| S:125 E:132 ||| CD
dye  ||| S:132 E:136 ||| JJ
laser  ||| S:136 E:142 ||| NN
therapy  ||| S:142 E:150 ||| NN
for  ||| S:150 E:154 ||| IN
Mibelli  ||| S:154 E:162 ||| NNP
angiokeratoma.  ||| S:162 E:177 ||| CD
50  ||| S:177 E:180 ||| CD
cases  ||| S:180 E:186 ||| NNS
of  ||| S:186 E:189 ||| IN
Mibelli  ||| S:189 E:197 ||| NNP
angiokeratoma ||| S:197 E:210 ||| NN
,  ||| S:210 E:212 ||| ,
from  ||| S:212 E:217 ||| IN
10  ||| S:217 E:220 ||| CD
to  ||| S:220 E:223 ||| TO
41  ||| S:223 E:226 ||| CD
year-oldï¼Œwere  ||| S:226 E:240 ||| CD
treated  ||| S:240 E:248 ||| VBN
with  ||| S:248 E:253 ||| IN
the  ||| S:253 E:257 ||| DT
595nm  ||| S:257 E:263 ||| FW
pulsed  ||| S:263 E:270 ||| FW
dye  ||| S:270 E:274 ||| FW
laser ||| S:274 E:279 ||| FW
.  ||| S:279 E:281 ||| .
The  ||| S:281 E:285 ||| DT
parameters  ||| S:285 E:296 ||| NN
were  ||| S:296 E:301 ||| VBD
as  ||| S:301 E:304 ||| RB
follows ||| S:304 E:311 ||| VBZ
:  ||| S:311 E:313 ||| :
a  ||| S:313 E:315 ||| DT
wavelength  ||| S:315 E:326 ||| NN
of  ||| S:326 E:329 ||| IN
595  ||| S:329 E:333 ||| CD
nm ||| S:333 E:335 ||| NN
,  ||| S:335 E:337 ||| ,
pulse  ||| S:337 E:343 ||| JJ
duration  ||| S:343 E:352 ||| NN
of  ||| S:352 E:355 ||| IN
10ms ||| S:355 E:359 ||| NNP
,  ||| S:359 E:361 ||| ,
spot  ||| S:361 E:366 ||| NN
size  ||| S:366 E:371 ||| NN
of  ||| S:371 E:374 ||| IN
7  ||| S:374 E:376 ||| CD
mm  ||| S:376 E:379 ||| NNS
and  ||| S:379 E:383 ||| CC
energy  ||| S:383 E:390 ||| NN
fluency  ||| S:390 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
12.0-13.5  ||| S:401 E:411 ||| NNP
J ||| S:411 E:412 ||| NNP
/ ||| S:412 E:413 ||| FW
cm ||| S:413 E:415 ||| FW
( ||| S:415 E:416 ||| -LRB-
2 ||| S:416 E:417 ||| LS
) ||| S:417 E:418 ||| -RRB-
.  ||| S:418 E:420 ||| .
The  ||| S:420 E:424 ||| DT
treatments  ||| S:424 E:435 ||| NNS
were  ||| S:435 E:440 ||| VBD
repeated  ||| S:440 E:449 ||| VBN
at  ||| S:449 E:452 ||| IN
intervals  ||| S:452 E:462 ||| NNS
of  ||| S:462 E:465 ||| IN
4-6  ||| S:465 E:469 ||| CD
weeks  ||| S:469 E:475 ||| NNS
until  ||| S:475 E:481 ||| IN
the  ||| S:481 E:485 ||| DT
lesion  ||| S:485 E:492 ||| NN
was  ||| S:492 E:496 ||| VBD
cleared ||| S:496 E:503 ||| VBN
,  ||| S:503 E:505 ||| ,
or  ||| S:505 E:508 ||| CC
the  ||| S:508 E:512 ||| DT
parents  ||| S:512 E:520 ||| NNS
discontinued  ||| S:520 E:533 ||| VBN
the  ||| S:533 E:537 ||| DT
treatment ||| S:537 E:546 ||| NN
.  ||| S:546 E:548 ||| .
Detailed  ||| S:548 E:557 ||| JJ
demographics  ||| S:557 E:570 ||| NNS
and  ||| S:570 E:574 ||| CC
the  ||| S:574 E:578 ||| DT
assessment  ||| S:578 E:589 ||| NN
of  ||| S:589 E:592 ||| IN
the  ||| S:592 E:596 ||| DT
degree  ||| S:596 E:603 ||| NN
of  ||| S:603 E:606 ||| IN
lesion  ||| S:606 E:613 ||| JJ
clearance  ||| S:613 E:623 ||| NN
were  ||| S:623 E:628 ||| VBD
statistically  ||| S:628 E:642 ||| RB
analyzed  ||| S:642 E:651 ||| VBN
through  ||| S:651 E:659 ||| IN
SASS18.0 ||| S:659 E:667 ||| CD
.  ||| S:667 E:669 ||| .
All  ||| S:669 E:673 ||| PDT
the  ||| S:673 E:677 ||| DT
50  ||| S:677 E:680 ||| CD
patients  ||| S:680 E:689 ||| NNS
were  ||| S:689 E:694 ||| VBD
treated  ||| S:694 E:702 ||| VBN
1-4  ||| S:702 E:706 ||| CD
times ||| S:706 E:711 ||| NNS
.  ||| S:711 E:713 ||| .
The  ||| S:713 E:717 ||| DT
total  ||| S:717 E:723 ||| JJ
rate  ||| S:723 E:728 ||| NN
of  ||| S:728 E:731 ||| IN
significant  ||| S:731 E:743 ||| JJ
improvement  ||| S:743 E:755 ||| NN
was  ||| S:755 E:759 ||| VBD
80 ||| S:759 E:761 ||| CD
% ||| S:761 E:762 ||| NN
,  ||| S:762 E:764 ||| ,
and  ||| S:764 E:768 ||| CC
the  ||| S:768 E:772 ||| DT
rate  ||| S:772 E:777 ||| NN
of  ||| S:777 E:780 ||| IN
full  ||| S:780 E:785 ||| JJ
recovery  ||| S:785 E:794 ||| NN
was  ||| S:794 E:798 ||| VBD
30 ||| S:798 E:800 ||| CD
% ||| S:800 E:801 ||| NN
.  ||| S:801 E:803 ||| .
We  ||| S:803 E:806 ||| PRP
failed  ||| S:806 E:813 ||| VBD
to  ||| S:813 E:816 ||| TO
find  ||| S:816 E:821 ||| VB
statistical  ||| S:821 E:833 ||| JJ
significance  ||| S:833 E:846 ||| NN
between  ||| S:846 E:854 ||| IN
genders ||| S:854 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
or  ||| S:863 E:866 ||| CC
the  ||| S:866 E:870 ||| DT
size  ||| S:870 E:875 ||| NN
and  ||| S:875 E:879 ||| CC
color  ||| S:879 E:885 ||| NN
of  ||| S:885 E:888 ||| IN
lesions ||| S:888 E:895 ||| NNS
,  ||| S:895 E:897 ||| ,
which  ||| S:897 E:903 ||| WDT
might  ||| S:903 E:909 ||| MD
be  ||| S:909 E:912 ||| VB
due  ||| S:912 E:916 ||| JJ
to  ||| S:916 E:919 ||| TO
limited  ||| S:919 E:927 ||| JJ
sample  ||| S:927 E:934 ||| NN
size ||| S:934 E:938 ||| NN
.  ||| S:938 E:940 ||| .
The  ||| S:940 E:944 ||| DT
most  ||| S:944 E:949 ||| RBS
common  ||| S:949 E:956 ||| JJ
adverse  ||| S:956 E:964 ||| JJ
effects  ||| S:964 E:972 ||| NNS
after  ||| S:972 E:978 ||| IN
treatment  ||| S:978 E:988 ||| NN
were  ||| S:988 E:993 ||| VBD
purpura  ||| S:993 E:1001 ||| JJ
and  ||| S:1001 E:1005 ||| CC
edema ||| S:1005 E:1010 ||| NN
,  ||| S:1010 E:1012 ||| ,
which  ||| S:1012 E:1018 ||| WDT
usually  ||| S:1018 E:1026 ||| RB
lasted  ||| S:1026 E:1033 ||| VBN
for  ||| S:1033 E:1037 ||| IN
12  ||| S:1037 E:1040 ||| CD
h  ||| S:1040 E:1042 ||| NN
to  ||| S:1042 E:1045 ||| TO
several  ||| S:1045 E:1053 ||| JJ
days ||| S:1053 E:1057 ||| NNS
.  ||| S:1057 E:1059 ||| .
Temporary  ||| S:1059 E:1069 ||| JJ
pigment  ||| S:1069 E:1077 ||| NN
alterations  ||| S:1077 E:1089 ||| NNS
were  ||| S:1089 E:1094 ||| VBD
not  ||| S:1094 E:1098 ||| RB
common ||| S:1098 E:1104 ||| JJ
.  ||| S:1104 E:1106 ||| .
Other  ||| S:1106 E:1112 ||| JJ
side  ||| S:1112 E:1117 ||| NN
effects  ||| S:1117 E:1125 ||| NNS
such  ||| S:1125 E:1130 ||| JJ
as  ||| S:1130 E:1133 ||| IN
scar  ||| S:1133 E:1138 ||| NN
or  ||| S:1138 E:1141 ||| CC
skin  ||| S:1141 E:1146 ||| NN
texture  ||| S:1146 E:1154 ||| NN
change  ||| S:1154 E:1161 ||| NN
were  ||| S:1161 E:1166 ||| VBD
not  ||| S:1166 E:1170 ||| RB
observed ||| S:1170 E:1178 ||| VBD
.  ||| S:1178 E:1180 ||| .
Our  ||| S:1180 E:1184 ||| PRP$
experience  ||| S:1184 E:1195 ||| NN
confirmed  ||| S:1195 E:1205 ||| VBD
the  ||| S:1205 E:1209 ||| DT
clinical  ||| S:1209 E:1218 ||| JJ
efficacy  ||| S:1218 E:1227 ||| NN
and  ||| S:1227 E:1231 ||| CC
safety  ||| S:1231 E:1238 ||| NN
of  ||| S:1238 E:1241 ||| IN
the  ||| S:1241 E:1245 ||| DT
595  ||| S:1245 E:1249 ||| CD
nm  ||| S:1249 E:1252 ||| NNS
pulse  ||| S:1252 E:1258 ||| VBP
dye  ||| S:1258 E:1262 ||| JJ
laser  ||| S:1262 E:1268 ||| NN
in  ||| S:1268 E:1271 ||| IN
the  ||| S:1271 E:1275 ||| DT
treatment  ||| S:1275 E:1285 ||| NN
of  ||| S:1285 E:1288 ||| IN
Mibelli  ||| S:1288 E:1296 ||| NNP
angiokeratoma ||| S:1296 E:1309 ||| NN
.  ||| S:1309 E:1311 ||| .
